ADMA · Adma Biologics Inc
United States · RS rating 69 · As of 2026-11-03
| Price | 11.11 USD |
|---|---|
| 1-day change | +0.5% |
| RS rating (overall / 1M / 3M / 12M) | 69 / 82 / 89 / 32 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 28 / 24 / 25 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +33.3% |
| Sales growth Q/Q | +3.7% |
| Distance from 52-week high | +45.5% |
| Market cap (USD) | $2.6B |